TY - JOUR T1 - mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients JF - Life Science Alliance JO - Life Sci. Alliance DO - 10.26508/lsa.202201381 VL - 5 IS - 6 SP - e202201381 AU - Elena Azzolini AU - Chiara Pozzi AU - Luca Germagnoli AU - Bianca Oresta AU - Nicola Carriglio AU - Mariella Calleri AU - Carlo Selmi AU - Maria De Santis AU - Silvia Finazzi AU - Carmelo Carlo-Stella AU - Alexia Bertuzzi AU - Francesca Motta AU - Angela Ceribelli AU - Alberto Mantovani AU - Fabrizio Bonelli AU - Maria Rescigno Y1 - 2022/06/01 UR - https://www.life-science-alliance.org/content/5/6/e202201381.abstract N2 - SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is progressively us allowing to overcome the pandemic. Recent evidence has shown that response to vaccination in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-γ T-cell response in 328 subjects, including 131 immunocompromised individuals (cancer, rheumatologic, and hemodialysis patients), 160 health-care workers (HCW) and 37 subjects older than 75 yr, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according to the type of treatment. We found that immunocompromised patients, depending on the type of treatment, poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-CoV-2–specific immune response than those who are vaccinated without prior infection. ER -